JP2020515518A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515518A5 JP2020515518A5 JP2019538382A JP2019538382A JP2020515518A5 JP 2020515518 A5 JP2020515518 A5 JP 2020515518A5 JP 2019538382 A JP2019538382 A JP 2019538382A JP 2019538382 A JP2019538382 A JP 2019538382A JP 2020515518 A5 JP2020515518 A5 JP 2020515518A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- acid sequence
- seq
- polypeptide
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 229920001184 polypeptide Polymers 0.000 claims 19
- 102000004196 processed proteins & peptides Human genes 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 19
- 150000001875 compounds Chemical class 0.000 claims 18
- 210000004899 c-terminal region Anatomy 0.000 claims 12
- 102000004169 proteins and genes Human genes 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 108060003951 Immunoglobulin Proteins 0.000 claims 9
- 102000018358 immunoglobulin Human genes 0.000 claims 9
- 150000005829 chemical entities Chemical class 0.000 claims 7
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 claims 6
- 150000001413 amino acids Chemical class 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 3
- 210000002966 serum Anatomy 0.000 claims 3
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 claims 2
- 241000282412 Homo Species 0.000 claims 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 claims 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 102000006395 Globulins Human genes 0.000 claims 1
- 108010044091 Globulins Proteins 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 235000003976 Ruta Nutrition 0.000 claims 1
- 240000005746 Ruta graveolens Species 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 108020001507 fusion proteins Proteins 0.000 claims 1
- 102000037865 fusion proteins Human genes 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 235000005806 ruta Nutrition 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022196232A JP7628996B2 (ja) | 2017-01-17 | 2022-12-08 | 改善された血清アルブミン結合剤 |
| JP2024204085A JP2025026992A (ja) | 2017-01-17 | 2024-11-22 | 改善された血清アルブミン結合剤 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762446988P | 2017-01-17 | 2017-01-17 | |
| US62/446,988 | 2017-01-17 | ||
| PCT/EP2018/051083 WO2018134235A1 (en) | 2017-01-17 | 2018-01-17 | Improved serum albumin binders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022196232A Division JP7628996B2 (ja) | 2017-01-17 | 2022-12-08 | 改善された血清アルブミン結合剤 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515518A JP2020515518A (ja) | 2020-05-28 |
| JP2020515518A5 true JP2020515518A5 (OSRAM) | 2021-01-07 |
| JP7219220B2 JP7219220B2 (ja) | 2023-02-07 |
Family
ID=61521465
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019538382A Active JP7219220B2 (ja) | 2017-01-17 | 2018-01-17 | 改善された血清アルブミン結合剤 |
| JP2022196232A Active JP7628996B2 (ja) | 2017-01-17 | 2022-12-08 | 改善された血清アルブミン結合剤 |
| JP2024204085A Pending JP2025026992A (ja) | 2017-01-17 | 2024-11-22 | 改善された血清アルブミン結合剤 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022196232A Active JP7628996B2 (ja) | 2017-01-17 | 2022-12-08 | 改善された血清アルブミン結合剤 |
| JP2024204085A Pending JP2025026992A (ja) | 2017-01-17 | 2024-11-22 | 改善された血清アルブミン結合剤 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US11414481B2 (OSRAM) |
| EP (3) | EP4442707A3 (OSRAM) |
| JP (3) | JP7219220B2 (OSRAM) |
| KR (2) | KR102662499B1 (OSRAM) |
| CN (2) | CN110191896B (OSRAM) |
| AU (2) | AU2018209151B2 (OSRAM) |
| BR (1) | BR112019014599A2 (OSRAM) |
| CA (1) | CA3050575A1 (OSRAM) |
| DK (1) | DK3571225T3 (OSRAM) |
| ES (1) | ES2991459T3 (OSRAM) |
| FI (1) | FI3571225T3 (OSRAM) |
| HR (1) | HRP20241469T1 (OSRAM) |
| HU (1) | HUE068790T2 (OSRAM) |
| IL (2) | IL267894B2 (OSRAM) |
| LT (1) | LT3571225T (OSRAM) |
| MX (2) | MX2019008496A (OSRAM) |
| PT (1) | PT3571225T (OSRAM) |
| RS (1) | RS66117B1 (OSRAM) |
| SG (2) | SG11201906264YA (OSRAM) |
| SI (1) | SI3571225T1 (OSRAM) |
| WO (1) | WO2018134235A1 (OSRAM) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11644471B2 (en) | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| PL2723769T5 (pl) | 2011-06-23 | 2022-10-17 | Ablynx Nv | Techniki przewidywania, wykrywania i redukcji niespecyficznej interferencji białka w testach z udziałem pojedynczych domen zmiennych immunoglobuliny |
| RU2765384C2 (ru) | 2016-12-07 | 2022-01-28 | Аблинкс Нв | Улучшенные одиночные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином |
| BR112019014600A2 (pt) | 2017-01-17 | 2020-02-18 | Ablynx N.V. | Ligantes de albumina sérica melhorados |
| DK3571225T3 (da) * | 2017-01-17 | 2024-11-04 | Ablynx Nv | Forbedrede serumalbuminbindere |
| CN114980923A (zh) | 2019-12-06 | 2022-08-30 | 艾伯霖克斯公司 | 包含靶向TNFα和OX40L的免疫球蛋白单可变结构域的多肽 |
| WO2021110816A1 (en) | 2019-12-06 | 2021-06-10 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TNFα AND IL-23 |
| MY208649A (en) | 2019-12-09 | 2025-05-22 | Sanofi Sa | Polypeptides comprising immunoglobulin single variable domains targeting il-13 and tslp |
| WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
| US20230136595A1 (en) | 2020-03-30 | 2023-05-04 | Ablynx Nv | Method for the production and purification of multivalent immunoglobulin single variable domains |
| KR20230074527A (ko) | 2020-09-25 | 2023-05-30 | 아블린쓰 엔.브이. | Il-13 및 ox40l을 표적으로 하는 면역글로불린 단일 가변 도메인을 포함하는 폴리펩티드 |
| WO2022129572A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
| PH12023500009A1 (en) | 2020-12-18 | 2024-03-11 | Ablynx Nv | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| EP4262985A1 (en) | 2020-12-18 | 2023-10-25 | Ablynx N.V. | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| JP2024546916A (ja) | 2021-12-17 | 2024-12-26 | アブリンクス エン．ヴェー． | ＴＣＲαβ、ＣＤ３３及びＣＤ１２３を標的とする免疫グロブリン単一可変ドメインを含むポリペプチド |
| AU2023290487A1 (en) | 2022-06-14 | 2025-01-30 | Ablynx Nv | Immunoglobulin single variable domains targeting t cell receptor |
| TW202423965A (zh) | 2022-07-27 | 2024-06-16 | 比利時商艾伯霖克斯公司 | 與新生兒fc受體的特定表位結合之多肽 |
| WO2024084203A1 (en) | 2022-10-18 | 2024-04-25 | Isogenica Limited | Single domain antibodies binding to albumin |
| TW202440614A (zh) | 2022-12-23 | 2024-10-16 | 比利時商艾伯霖克斯公司 | 基於蛋白質的接合載體 |
| CN120529914A (zh) | 2023-01-09 | 2025-08-22 | 奥德赛治疗股份有限公司 | 抗tnfr2抗原结合蛋白及其用途 |
| CN120712282A (zh) | 2023-02-17 | 2025-09-26 | 阿布林克斯有限公司 | 结合新生儿fc受体的多肽 |
| TW202444757A (zh) | 2023-03-14 | 2024-11-16 | 美商奧迪希治療公司 | 抗cd25抗原結合蛋白及其用途 |
| AU2024273077A1 (en) | 2023-05-17 | 2025-11-13 | Odyssey Therapeutics, Inc. | Modified single-domain antibodies |
| KR102822958B1 (ko) * | 2023-05-23 | 2025-06-20 | 대한민국(해양경찰청 해양경찰연구센터장) | 고래 불법포획 감식용 신속진단키트 |
| WO2024261235A1 (en) | 2023-06-22 | 2024-12-26 | Ablynx Nv | Chimeric proteins for modulating cytokine receptor activity |
| AR133108A1 (es) | 2023-06-29 | 2025-08-27 | Odyssey Therapeutics Inc | Proteínas de unión a antígeno anti-trailr2 y sus usos |
| TW202517676A (zh) | 2023-07-05 | 2025-05-01 | 比利時商艾伯霖克斯公司 | 用於治療ＩｇＧ相關疾病及病症之改良ＦｃＲｎ拮抗劑 |
| TW202525843A (zh) | 2023-09-04 | 2025-07-01 | 法商賽諾菲公司 | 用於治療表現磷脂醯肌醇蛋白聚糖-3之腫瘤的多肽 |
| WO2025061919A1 (en) | 2023-09-22 | 2025-03-27 | Ablynx Nv | Bi- and multivalent albumin binders |
| TW202530265A (zh) | 2023-10-13 | 2025-08-01 | 美商奧迪希治療公司 | 抗cdh17抗原結合蛋白及其用途 |
| WO2025099632A1 (en) | 2023-11-08 | 2025-05-15 | Sanofi | Cd25 based lysosomal degrader and uses thereof |
| US20250296991A1 (en) | 2023-12-01 | 2025-09-25 | Ablynx N.V. | Precision activated polypeptides |
| WO2025133166A1 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based carriers for site-specific amine conjugation |
| WO2025133253A2 (en) | 2023-12-22 | 2025-06-26 | Ablynx Nv | Protein-based conjugation carriers for intranuclear delivery |
| WO2025217240A1 (en) | 2024-04-10 | 2025-10-16 | Odyssey Therapeutics, Inc. | Anti-tnfr2 antigen-binding proteins and uses thereof |
| WO2025217488A1 (en) * | 2024-04-12 | 2025-10-16 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
| US12459994B2 (en) | 2024-04-12 | 2025-11-04 | Paragon Therapeutics, Inc. | Albumin binding proteins and methods of use |
| WO2025255558A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Anti-thymic stromal lymphopoietin (tslp) antigen-binding proteins and uses thereof |
| WO2025255435A2 (en) | 2024-06-07 | 2025-12-11 | Odyssey Therapeutics, Inc. | Antigen-binding proteins against serum albumin and uses thereof |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| EP1027439B1 (en) | 1997-10-27 | 2010-03-17 | Bac Ip B.V. | Multivalent antigen-binding proteins |
| US6742038B2 (en) | 2000-04-07 | 2004-05-25 | Danger, Inc. | System and method of linking user identification to a subscriber identification module |
| JP2005289809A (ja) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | 突然変異重鎖抗体 |
| US9321832B2 (en) * | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| DE60305919T2 (de) | 2002-06-28 | 2007-01-18 | Domantis Limited, Cambridge | Dual-specifische liganden mit erhöhter halbwertszeit |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| NZ540194A (en) | 2002-11-08 | 2008-07-31 | Ablynx Nv | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| JP2006517789A (ja) | 2003-01-10 | 2006-08-03 | アブリンクス エン．ヴェー． | 治療用ポリペプチド、その相同物、その断片、および血小板媒介凝集の調節での使用 |
| KR20070086896A (ko) | 2004-12-02 | 2007-08-27 | 도만티스 리미티드 | 항ｉｌ1ｒ1 단일 도메인 항체 및 치료적 용도 |
| CN103254309B (zh) | 2005-05-18 | 2017-09-26 | 埃博灵克斯股份有限公司 | 针对肿瘤坏死因子α的改进的纳米体TM |
| PL2444424T3 (pl) | 2005-05-20 | 2019-01-31 | Ablynx N.V. | Ulepszone Nanociała TM do leczenia zaburzeń, w których pośredniczy agregacja |
| CA2629850A1 (en) | 2005-12-01 | 2007-06-07 | Domantis Limited | Competitive domain antibody formats that bind interleukin 1 receptor type 1 |
| AU2006321364B2 (en) | 2005-12-01 | 2011-11-10 | Domantis Limited | Noncompetitive domain antibody formats that bind Interleukin 1 Receptor type 1 |
| FR2894741B1 (fr) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | Chaine de reception par satellite |
| AU2007209201A1 (en) | 2006-01-24 | 2007-08-02 | Domantis Limited | Fusion proteins that contain natural junctions |
| US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
| EP2069402A2 (en) | 2006-09-08 | 2009-06-17 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| NZ581097A (en) | 2007-05-24 | 2012-03-30 | Ablynx Nv | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| CA2706200A1 (en) | 2007-11-27 | 2009-06-04 | Ablynx N.V. | Immunoglobulin constructs comprising multiple single variable domains and an fc portion |
| DE102008023620A1 (de) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Funktionseinheit mit einer aufrufbaren Funktion und Verfahren zu deren Aufruf |
| MX2010012518A (es) | 2008-05-16 | 2010-12-06 | Ablynx Nv | Secuencias de aminoacidos dirigidas contra cxcr4 y otros receptores acoplados a proteina g y compuestos que comprenden los mismos. |
| CN102164965B (zh) * | 2008-09-26 | 2016-03-30 | Ucb医药有限公司 | 生物产品 |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| MX2012000765A (es) * | 2009-07-16 | 2012-02-13 | Glaxo Group Ltd | Dominios variables sencillos de union de albumina anti-suero mejorados. |
| CA2774552A1 (en) | 2009-09-30 | 2011-04-07 | Glaxo Group Limited | Drug fusions and conjugates with extended half life |
| EP2603522A1 (en) | 2010-08-13 | 2013-06-19 | GlaxoSmithKline Intellectual Property Development Limited | Improved anti-serum albumin binding variants |
| WO2012022703A2 (en) | 2010-08-20 | 2012-02-23 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| US11644471B2 (en) * | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP3363812A1 (en) * | 2011-06-23 | 2018-08-22 | Ablynx NV | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobin single variable domains |
| PL2723769T5 (pl) * | 2011-06-23 | 2022-10-17 | Ablynx Nv | Techniki przewidywania, wykrywania i redukcji niespecyficznej interferencji białka w testach z udziałem pojedynczych domen zmiennych immunoglobuliny |
| US20150344568A1 (en) * | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP4218933A1 (en) | 2011-06-23 | 2023-08-02 | Ablynx NV | Serum albumin binding proteins |
| WO2012174741A1 (en) | 2011-06-24 | 2012-12-27 | Google Inc. | Determining cross-language query suggestion based on query translations |
| MY167125A (en) | 2011-08-17 | 2018-08-13 | Glaxo Group Ltd | Modified proteins and peptides |
| US20130129727A1 (en) * | 2011-11-17 | 2013-05-23 | Nanjingjinsirui Science & Technology Biology Corporation | Methods and systems for increasing protein stability |
| WO2014037419A1 (en) | 2012-09-04 | 2014-03-13 | Vib Vzw | Immunoglobulin single variable domains directed against cd74 and uses derived thereof |
| US20140186365A1 (en) * | 2013-01-03 | 2014-07-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| SG10201810124PA (en) | 2014-05-16 | 2018-12-28 | Ablynx Nv | Improved immunoglobulin variable domains |
| CN114478753A (zh) | 2015-01-21 | 2022-05-13 | 英伊布里克斯公司 | 非免疫原性单结构域抗体 |
| LT3611192T (lt) | 2015-05-13 | 2025-06-25 | Ablynx N.V. | T ląstelių rekrutingo polipeptidai tcr alfa/beta reaktyvumo pagrindu |
| EP3374392B1 (en) * | 2015-11-13 | 2021-11-24 | Ablynx NV | Improved serum albumin-binding immunoglobulin variable domains |
| BR112018010802A2 (pt) | 2015-11-27 | 2018-11-27 | Ablynx Nv | polipeptídeos que inibem cd40l |
| RU2765384C2 (ru) | 2016-12-07 | 2022-01-28 | Аблинкс Нв | Улучшенные одиночные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином |
| DK3571225T3 (da) | 2017-01-17 | 2024-11-04 | Ablynx Nv | Forbedrede serumalbuminbindere |
| BR112019014600A2 (pt) * | 2017-01-17 | 2020-02-18 | Ablynx N.V. | Ligantes de albumina sérica melhorados |
| WO2025061919A1 (en) * | 2023-09-22 | 2025-03-27 | Ablynx Nv | Bi- and multivalent albumin binders |
-
2018
- 2018-01-17 DK DK18707848.0T patent/DK3571225T3/da active
- 2018-01-17 CN CN201880007313.6A patent/CN110191896B/zh active Active
- 2018-01-17 HU HUE18707848A patent/HUE068790T2/hu unknown
- 2018-01-17 EP EP24191388.8A patent/EP4442707A3/en active Pending
- 2018-01-17 BR BR112019014599-0A patent/BR112019014599A2/pt unknown
- 2018-01-17 IL IL267894A patent/IL267894B2/en unknown
- 2018-01-17 EP EP18707848.0A patent/EP3571225B1/en active Active
- 2018-01-17 WO PCT/EP2018/051083 patent/WO2018134235A1/en not_active Ceased
- 2018-01-17 EP EP24191393.8A patent/EP4442709A3/en active Pending
- 2018-01-17 HR HRP20241469TT patent/HRP20241469T1/hr unknown
- 2018-01-17 US US16/477,918 patent/US11414481B2/en active Active
- 2018-01-17 MX MX2019008496A patent/MX2019008496A/es unknown
- 2018-01-17 RS RS20241215A patent/RS66117B1/sr unknown
- 2018-01-17 AU AU2018209151A patent/AU2018209151B2/en active Active
- 2018-01-17 SG SG11201906264YA patent/SG11201906264YA/en unknown
- 2018-01-17 JP JP2019538382A patent/JP7219220B2/ja active Active
- 2018-01-17 LT LTEPPCT/EP2018/051083T patent/LT3571225T/lt unknown
- 2018-01-17 PT PT187078480T patent/PT3571225T/pt unknown
- 2018-01-17 SI SI201831169T patent/SI3571225T1/sl unknown
- 2018-01-17 CN CN202311123454.3A patent/CN117285623A/zh active Pending
- 2018-01-17 KR KR1020197024113A patent/KR102662499B1/ko active Active
- 2018-01-17 SG SG10202108972RA patent/SG10202108972RA/en unknown
- 2018-01-17 ES ES18707848T patent/ES2991459T3/es active Active
- 2018-01-17 IL IL312292A patent/IL312292A/en unknown
- 2018-01-17 KR KR1020247002265A patent/KR20240013861A/ko not_active Ceased
- 2018-01-17 CA CA3050575A patent/CA3050575A1/en active Pending
- 2018-01-17 FI FIEP18707848.0T patent/FI3571225T3/fi active
-
2019
- 2019-07-16 MX MX2023005374A patent/MX2023005374A/es unknown
-
2022
- 2022-06-29 US US17/852,604 patent/US20230060574A1/en active Pending
- 2022-12-08 JP JP2022196232A patent/JP7628996B2/ja active Active
-
2024
- 2024-11-22 JP JP2024204085A patent/JP2025026992A/ja active Pending
-
2025
- 2025-05-13 AU AU2025203430A patent/AU2025203430A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515518A5 (OSRAM) | ||
| JP2020506898A5 (OSRAM) | ||
| JP7453206B2 (ja) | 改良された血清アルブミン結合剤 | |
| RU2022101604A (ru) | Улучшенные отдельные вариабельные домены иммуноглобулина, связывающиеся с сывороточным альбумином | |
| AU2016351710B2 (en) | Improved serum albumin-binding immunoglobulin variable domains | |
| IL305912A (en) | Improved serum albumin binders | |
| JP2018537421A5 (OSRAM) | ||
| IL312292A (en) | Improved serum albumin binders | |
| JPWO2020069028A5 (OSRAM) | ||
| JP2020500510A5 (OSRAM) | ||
| JP2017519503A5 (OSRAM) | ||
| JPWO2022111425A5 (OSRAM) | ||
| RU2023110757A (ru) | Усовершенствованные агенты, связывающие сывороточный альбумин | |
| RU2023102139A (ru) | Усовершенствованные связывающиеся с сывороточным альбумином вещества | |
| RU2019118441A (ru) | Рекрутирующие т-клетки полипептиды, способные связывать cd123 и tcr альфа/бета |